FindTrial
Sign In

Resiquimod

DRUG11 trials

Sponsors

Graceway Pharmaceuticals, LLC, Mayo Clinic, Celldex Therapeutics, University of British Columbia, Craig L Slingluff, Jr

Conditions

Advanced MalignanciesInfluenza Vaccination in SeniorsMelanomaMelanoma (Skin)Metastatic MelanomaMucosal MelanomaRecurrent MelanomaStage IIA Melanoma

Early Phase 1

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery
CompletedNCT00470379
Mayo ClinicMelanoma (Skin)
Start: 2006-04-30End: 2011-10-31Updated: 2014-10-31
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
CompletedNCT01748747
Mayo ClinicRecurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma +5
Start: 2012-10-31End: 2017-03-30Updated: 2018-10-09

Phase 1

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
CompletedNCT00948961
Celldex TherapeuticsAdvanced Malignancies
Start: 2009-09-30End: 2014-02-28Updated: 2016-06-27
Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists
CompletedNCT01737580
University of British ColumbiaInfluenza Vaccination in Seniors
Start: 2013-04-30End: 2013-06-30Updated: 2013-08-28
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
CompletedNCT02126579
Craig L Slingluff, JrMelanoma, Metastatic Melanoma, Mucosal Melanoma
Start: 2014-05-01End: 2021-05-05Updated: 2024-02-28

Phase 2

Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
CompletedNCT00114920
Graceway Pharmaceuticals, LLCWarts
Start: 2004-03-31Target: 88Updated: 2007-02-19
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
CompletedNCT00115141
Graceway Pharmaceuticals, LLCWarts
Start: 2004-04-30Target: 88Updated: 2007-02-19
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
CompletedNCT00116675
Graceway Pharmaceuticals, LLCWarts
Start: 2005-03-31End: 2006-04-30Target: 84Updated: 2007-02-19
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
CompletedNCT00116662
Graceway Pharmaceuticals, LLCWarts
Start: 2005-03-31Target: 84Updated: 2007-02-19
Study With a Topical Gel to Treat Common Warts in Adults
CompletedNCT00117871
Graceway Pharmaceuticals, LLCWarts
Start: 2004-10-31Target: 48Updated: 2007-02-19
Study With a Topical Gel to Treat Common Warts in Adults
CompletedNCT00117923
Graceway Pharmaceuticals, LLCWarts
Start: 2004-08-31Target: 88Updated: 2007-02-19

Related Papers

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
Journal for ImmunoTherapy of Cancer2021-08-0158 citations
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma.
Journal of Clinical Oncology2018-05-203 citations